Teriparatide ntsiav tshuaj(BPTH 1-34) yog ib qho kev tsim ntawm qhov ncauj ntawm tib neeg parathyroid hormone (1-34). Qhov txawv ntawm cov qauv txhaj tshuaj thiab cov tshuaj tiv thaiv resorptive, nws yog tus cwj pwm los ntawm qhov ncauj osteoanabolic nkaus thiab tsim tshwj xeeb rau cov neeg mob osteoporosis ntawm kev pheej hmoo pob txha. Raws li cov ntsiav tshuaj ntawm qhov ncauj, nws tshem tawm qhov xav tau ntawm kev txhaj tshuaj, ua rau muaj kev txhim kho kev noj qab haus huv. Nws yog precisely absorbed ntawm lub plab hnyuv ib ntsuj av tau thaum tuav ruaj khov pharmacological kev ua.
Peb Cov Khoom Muag Khoom
Teriparatide COA
Kev kho mob ntawm Fibrous Dysplasia ntawm pob txha
Fibrous dysplasia ntawm pob txha yog ib qho teeb meem ntawm kev loj hlob ntawm cov pob txha uas muaj kev hloov pauv ntawm cov pob txha nrog cov ntaub so ntswg txawv txav, ua rau cov pob txha fragility, mob, thiab kev kho mob tsis tshua muaj kev xaiv.Teriparatide ntsiav tshuajmodulates pob txha metabolism thiab txhawb kev tsim ntawm cov pob txha ib txwm muaj cov ntaub so ntswg, yog li ameliorating skeletal abnormalities, relieving mob, thiab txhim kho limb muaj nuj nqi. Nws activates osteoblasts los txhawb kev tsim cov pob txha ib txwm hloov cov ntaub so ntswg txawv txav, thaum inhibiting fiber ntau proliferation thiab slowing kev loj hlob ntawm pob txha deformity.
Txhim kho ntawm Orthopedic Implant Stability
Kev ruaj ntseg ntawm orthopedic implants ncaj qha txiav txim siab txog kev phais. Osteoporosis thiab lwm yam cuam tshuam txo cov pob txha-implant integration, predisposing rau cov teeb meem xws li loosening thiab migration. Nws txhawb cov pob txha tsim nyob ib ncig ntawm kev cog hniav, txhim kho osseointegration, thiab prolongs implant lifespan. Los ntawm activating osteoblasts, nws accelerates pob txha matrix synthesis thiab mineralization ntawm lub implant interface, tsim ib tug ruaj khov pob txha-cog daim ntawv cog lus thiab txo peri - cog pob txha poob.
Tus Kheej thiab Precision Tshuaj
Kho cov lus teb rauTeriparatide ntsiav tshuajtxawv tus kheej. Daim ntawv thov kev txiav txim siab tuaj yeem ua tiav los ntawm genotyping, kev kwv yees kev txawj ntse, kev pheej hmoo ntawm kev sib tw, thiab lwm txoj hauv kev los txhim kho cov txiaj ntsig kho mob.
(1) Genotype-Txoj Kev Kho Mob
Polymorphisms hauv PTH1R noob cuam tshuam BPTH 1-34 kev ua tau zoo, nrog rau rs10500783 locus ua haujlwm tseem ceeb biomarker. Cov neeg mob nqa CC genotype nthuav qhia PTH1R ntau dua, cov lus teb kho tau zoo dua, thiab cov pob txha pob txha pob txha ntau dua. Cov neeg uas muaj TT genotype qhia cov lus teb tsis zoo thiab yuav xav tau kev hloov kho. Genotyping txhawm rau txheeb xyuas cov genotypes uas muaj txiaj ntsig zoo txhim kho cov hom phiaj kho mob thiab zam kev siv tsis zoo ntawm cov peev txheej kho mob.
(2) Artificial Intelligence Prediction Models
AI qauv kev sib koom ua ke ntawm FRAX® cov cuab yeej ntsuas kev pheej hmoo ntawm pob txha thiab cov pob txha hloov pauv ua kom muaj kev kwv yees qhov tseeb ntawm kev kho mob thiab kev pheej hmoo ntawm pob txha. FRAX® kwv yees 10-xyoo kev puas tsuaj rau pob txha, thaum cov pob txha hloov pauv cov cim qhia txog cov pob txha metabolic. Los ntawm kev sib txuas cov ntaub ntawv no, tus qauv kwv yees cov pob txha pob txha pob txha pob txha pob txha txhim kho thiab txheeb xyuas cov neeg mob uas muaj kev pheej hmoo siab ntawm kev tsis zoo, txhawb nqa cov tswv yim noj tshuaj rau tus kheej.
(3) Polygenic Scoring System
Ib qho kev sib tw polygenic sib koom ua ke ntau cov pob txha metabolism-txog SNPs suav nrog rs10500783, rs2141976, thiab rs1561570 txhim kho qhov tseeb ntawm kev kwv yees ua tau zoo. Cov neeg mob tau stratified rau hauv siab, nruab nrab, thiab cov pab pawg tsawg kom tau txais cov kev kho kom haum, ntxiv kev kho kom zoo dua.
Kev tsim kho thiab kev siv cov qauv tshiab
Kev txhaj tshuaj BPTH 1-34 xav tau kev tswj hwm txhua hnub thiab cuam tshuam nrog kev ua tsis zoo. Kev loj hlob ntawm cov qauv tshiab yog tsom rau kev txhim kho kev siv tshuaj kom yooj yim, feem ntau suav nrog ntev - ua cov tshuaj txhaj, cov tshuaj tiv thaiv kab mob, thiab cov tshuab tso tawm hauv zos.
(1) Ntev-Kev Ua Txhaum Txhaum Cai
Siv kev txhawb nqa - tso tawm microsphere lossis nanotechnology, kev siv tshuaj ntau zaus raug txo mus rau ib zaug ib lub lim tiam lossis ib hlis. Sustained - tso tawm microsphere formulations encapsulate cov tshuaj nyob rau hauv biodegradable cov ntaub ntawv, ua kom qeeb tso tawm thiab ruaj khov plasma concentrations tom qab txhaj tshuaj. Kev ua tau zoo yog piv rau cov qauv tsim nrog tsawg dua qhov tsis zoo. Ntau qhov ntev - cov qauv ua yeeb yam yog nyob rau hauv kev sim tshuaj thiab xav tias yuav dhau los ua cov kev xaiv kho mob nyiam.
(2) Transdermal Patches
Transdermal thaj ua rau thaj xa cov tshuaj tsis tu ncua hla ntawm daim tawv nqaij yam tsis muaj kev txhaj tshuaj, haum rau cov neeg laus thiab cov neeg muaj koob phobia. Tam sim no hauv Phase II kev sim tshuaj, cov ntaub ntawv ua ntej qhia tau hais tias muaj txiaj ntsig zoo piv rau cov tshuaj txhaj tshuaj nrog cov xwm txheej tsis zoo. Kev siv ntau zaus yog kwv yees ib zaug lossis ob zaug hauv ib lub lis piam, txhim kho kev ua raws.
(3) Local Sustained -Tshawb Systems
Tsim los rau kev kho mob hauv zos ntawm pob txha thiab pob txha tsis xws luag, xws li PTH-collagen composite cov ntaub ntawv, cov tshuab no muab cov tshuaj tso tawm hauv zos, ua kom muaj zog hauv zos, txhim kho cov teebmeem kev kho mob, thiab txo cov kev mob tshwm sim. Cov kev tshawb fawb tsiaj tau lees paub tias cov platforms zoo li no txhim kho cov pob txha rov ua haujlwm zoo yam tsis muaj kev cuam tshuam rau lub cev.
Cov kev ceev faj
1. Siv nruj raws li kev saib xyuas kev kho mob. Tsis txhob kho nws tus kheej kom ntau npaum li cas, txuas ntxiv, lossis txo cov kev kho mob. Lub sijhawm kho mob niaj hnub yuav tsum tsis pub tshaj 24 lub hlis. Kev siv tsis tu ncua ntev yuav ua rau muaj kev pheej hmoo ntawm kev tsis zoo; Kev txiav tawm lossis kev hloov pauv yuav tsum tau coj los ntawm tus kws kho mob.
2. Ua haujlwm raws sijhawm txhua hnub, nrog lossis tsis muaj zaub mov. Yog tias tsis noj tshuaj, tsis txhob muab ob npaug rau qhov koob tshuaj ntxiv; rov pib noj cov tshuaj tsis tu ncua hnub tom qab kom tsis txhob muaj hypercalcemia los ntawm kev noj ntau dhau.
3. Tsis txhob siv cov tshuaj calcium ntau ntxiv lossis cov tshuaj vitamin D thaum lub sijhawm kho tshwj tsis yog tus kws kho mob qhia, txhawm rau txo qhov kev pheej hmoo ntawm hypercalcemia.
I. Core Raw Materials thiab Txheej Txheem Npaj
Core raw khoom ntawmTeriparatide ntsiav tshuajyog recombinant human parathyroid hormone (1–34), uas yog tsim los ntawm recombinant DNA technology siv Escherichia coli ua tus tswv hom. Cov thev naus laus zis no tuaj yeem ua raws li 34 amino acid ib ntus ntawm N-terminus ntawm endogenous human parathyroid hormone, kom ntseeg tau tias kev ua haujlwm lom neeg ntawm cov tshuaj zoo ib yam nrog cov tshuaj hormones ntuj. Thaum lub sij hawm tsim khoom, cov noob encoding tib neeg parathyroid hormone (1-34) yog thawj zaug nkag rau hauv Escherichia colistrain, uas yog tom qab ntawd fermented los qhia txog lub hom phiaj peptide saw hauv ntau qhov ntau.
Efficiency leap Precision thiab stability
High-purity BPTH 1-34 raw khoom yog tom qab tau txais los ntawm kev sib cais thiab purification.
Excipients rau cov ntsiav tshuaj ntawm qhov ncauj raug xaiv kom sib npaug tshuaj ruaj khov thiab kev ua haujlwm ntawm lub plab zom mov, feem ntau suav nrog cov fillers, disintegrants, penetration enhancers, thiab protease inhibitors. Ntawm lawv, cov tshuaj tiv thaiv kev nkag mus (xws li SNAC lossis nws cov derivatives) zoo txhim kho txoj hnyuv phab ntsa permeability thiab kev nqus tshuaj, thaum protease inhibitors txo cov tshuaj degradation hauv plab hnyuv thiab lav bioavailability.
II. Txheej txheem molding
Cov txheej txheem molding txheej txheem ntawm cov khoom siv cov txheej txheem cov ntsiav tshuaj ntau lawm, muaj tsib kauj ruam tseem ceeb: sib tov, granulation, ziab, ntsiav tshuaj, thiab txheej. Cov txheej txheem tsis raug tswj nruj me ntsis hauv txhua theem kom ntseeg tau tias cov ntsiav tshuaj zoo ib yam.
Ua ntej, purified BPTH 1-34 raw khoom thiab excipients yog sib xyaw ua ke nyob rau hauv kev faib ua feem, ua raws li los ntawm ntub granulation nrog ib tug tsim nyog tus nqi ntawm binder los tiv thaiv raw khoom aggregation uas yuav cuam tshuam rau kev ua hauj lwm ntawm dissolution. Tom qab ntawd cov granules tau qhuav ntawm qhov kub qis ntawm 40-50℃kom tsis txhob thermal degradation ntawm cov khoom siv roj ntsha.
Tom qab sizing, qhuav granules yog tov nrog ib tug lubricant thiab compressed rau hauv cov ntsiav tshuaj, nrog precisely tswj compression siab kom ua tau haum hardness thiab standard disintegration lub sij hawm. Thaum kawg, txheej zaj duab xis yog ua los ntawm kev siv cov khoom siv hauv plab-soluble txheej, uas tiv thaiv cov tshuaj los ntawm kev degradation hauv plab thiab ua kom tawg sai sai thiab tso tawm thaum nkag mus rau hauv txoj hnyuv, yog li txhim kho kev nqus tau zoo.
Cov txheej txheem no tau sib xws nrog cov cuab yeej siv tshuaj uas twb muaj lawm rau kev tsim khoom loj, muab qhov zoo ntawm cov nqi qis thiab kev ua haujlwm siab.
III. Kev Tswj Xyuas Zoo
Kev tswj xyuas cov khoom lag luam nruj me ntsis ua raws li Suav Pharmacopoeia 2025 Edition, USP (United States Pharmacopeia), thiab ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) cov lus qhia, npog tag nrho lub neej ntawm cov khoom siv raw thiab cov khoom nruab nrab rau cov khoom tiav.
Rau cov khoom siv raw, cov kev ntsuam xyuas tseem ceeb suav nrog purity, sib xws ntawm cov amino acid ib ntus, thiab cov ntsiab lus impurity. Kev soj ntsuam ntau ntawm peptide muaj pes tsawg leeg yog ua los ntawm kev ua haujlwm siab ua kua chromatography (HPLC) thiab kua chromatography-mass spectrometry (LC-MS).
Purity yuav tsum tsis pub tsawg tshaj 95.0% thiab tsis ntau tshaj 105.0%. Lub party cell protein thiab residual DNA yuav tsum tau raws li kev cai txwv.
Cov khoom nruab nrab raug sim rau granule flowability, particle loj faib, thiab cov ntsiab lus noo noo. Kev ntsuam xyuas cov khoom tiav suav nrog cov tsos, lub sijhawm tawg, kev sib cais, cov ntsiab lus sib xws, thiab kev txwv microbial. Lub sij hawm tawg yuav tsum tsis pub dhau 30 feeb, thiab kev sib cais yuav tsum ua kom tau raws li cov txheej txheem los xyuas kom meej cov tshuaj tso tawm sai hauv vivo. Tsis tas li ntawd, qhov ntsuas kub-humidity two-factor accelerated testing yog ua los xyuas kom meej qhov ruaj khov mus ntev.
IV. Kev ua raws li kev tsim khoom thiab kev tswj hwm
Kev tsim khoom ntawm cov khoom yuav tsum nruj me ntsis ua raws li GMP (Kev Tsim Khoom Zoo). Kev cob qhia ntau lawm yuav tsum ua kom tau raws li cov qauv kev huv huv biopharmaceutical, nrog rau kev tswj hwm ib puag ncig qhov kub thiab txias, av noo, cov teeb meem me me, thiab microbial suav kom tsis txhob muaj kab mob sib kis thaum tsim khoom.
Cov neeg tsim khoom yuav tsum tau tsim kom muaj kev ua tiav kev ua tiav, nrog rau cov ntaub ntawv rau txhua kauj ruam nrog rau kev yuav khoom raw, fermentation, purification, formulation, thiab ntim kom paub meej cov khoom traceability tag nrho.
Lub caij no, kev tsim khoom yuav tsum ua raws li kev cai tswj hwm ntawm ntau tus tub ceev xwm, xws li National Medical Products Administration (NMPA) ntawm Tuam Tshoj, US Food and Drug Administration (FDA), thiab European Medicines Agency (EMA).
Ob qho tshuaj tshiab thiab biosimilars yuav tsum dhau qhov kev sim tshuaj xyuas nruj thiab nyob ntawm qhov chaw GMP tshuaj xyuas ua ntej kev lag luam.
Tam sim no, ntau lub lag luam hauv tsev tau tso tawm BPTH 1-34-txog cov khoom lag luam. Tag nrho cov txheej txheem tsim khoom yuav tsum ua raws li qhov yuav tsum tau ua ntawm Pharmacopoeia tsab ntawv tshaj tawm, hloov kho cov ntaub ntawv ua haujlwm zoo, ntxiv dag zog rau cov neeg siv khoom tsim nyog tshawb xyuas, thiab xyuas kom meej tias cov khoom zoo raws li cov qauv thoob ntiaj teb.
Cov ntaub ntawv
Pawg Neeg Saib Xyuas Tshwj Xeeb rau Kev Txhim Kho Kev Txhim Kho ntawm Osteoporotic Fractures, Tuam Tshoj Koom Haum rau Kev Txhim Kho Tshuab Hloov Kho thiab Kev Txhim Kho, thiab al. Cov kws tshaj lij Suav pom zoo rau Teriparatide hauv Kev Kho Mob Osteoporotic Fractures (2024 Edition) [J]. National Medical Journal of China, 2024, 104(18): 1361–1370.
Chenhui Chuangju Biology. Kev Tshawb Fawb Txog Kev Tshawb Fawb ntawm BPTH 1-34 (Peptide Reference) [EB/OL]. CSDN Blog, 2026-03-13.
Orthopedic Team, 3201 Tsev Kho Mob Koom Tes rau Xi'an Jiaotong University Tsev Kawm Ntawv Tshuaj. Cov teebmeem ntawm BPTH 1-34 ntawm peri-prosthetic pob txha pob txha pob txha pob txha pob txha pob txha thiab pob txha pob txha ntawm sab femoral tom qab tag nrho lub duav arthroplasty [J]. Phau Ntawv Xov Xwm Suav ntawm Pob Txha thiab Pob Txha, 2023, 38(5): 489–492.
Silva, BC, et al. PTH1R structural dynamics hauv pob txha signaling [J]. Xwm, 2021, 592(7852): 112–116.
Hari R. Desu, Dinesh Aggrawal. Kev loj hlob ntawm Ntev -Kev Ua Haujlwm BPTH 1-34 Cov Qauv los Kho Osteoporosis [R]. DBT, Govt. Is Nrias teb, 2025.
Multifunctional Bone Repair Platform: Sequential Drug Release and Cytokine Scavenging for Osteoporotic Bone Defects [EB/OL].Suav Bulletin of Life Sciences, 2025-11-17.
Suav Clinical Trial Registry. Phase II Clinical Trial of BPTH 1-34 Transdermal Patch [EB/OL]. 2025-11-21.
Jilka, RL, et al. BPTH 1-34 txhim kho osteoblast sib txawv ntawm IGF-1 autocrine voj [J].Phau ntawv Journal of Bone and Mineral Research, 2020, 35(5): 912–924.
BPTH 1-34 Kev Kho Kho Kho Kom Zoo Dua Los Ntawm Cementless Tag Nrho Lub Hauv caug Arthroplasty: Ib Daim Ntawv Qhia [J].Phau ntawv Journal of Orthopedic Case Reports, 2017, 7(1): 32–35.
Wein, MN, et al. Tib -kev tshuaj xyuas ntawm tes ntawm PTH cov lus teb hauv osteocytes [J].Cell Xov Xwm, 2020, 30(8): 2590–2602.
Cim npe nrov: Tuam Tshoj teriparatide ntsiav tshuaj manufacturers, lwm tus neeg
